Helen Cameron

CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.

Citigroup Global Markets Australia Pty Ltd. (Citi Australia) is the brokerage arm of Citigroup Global Markets Australia Holdings Pty Ltd., ultimately held by Citigroup, Inc., (NYSE: C) in the US. Headquartered in Sydney with additional office in Melbourne, Citi Australia provides brokerage services to Australian consumers, corporations, institutions and governments. The firm participate in sales and trading across all asset classes including equities, corporate, government and agency bonds, mortgage-backed securities, syndicated loans, structured products, foreign exchange and futures.